Showing 168 results
-
Media Release /Novartis Healthcare Philippines was recognized by the National Committee for Sight Preservation (NCSP) for the company’s support to the NCSCP “Maging MATAlino”…
-
Media Release /RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i)…
-
Media Release /Ribociclib plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting NATALEE is the first and only positive Phase III…
-
Media Release /Chronic kidney disease (CKD) is among the leading causes of sickness and death in the Philippines. Latest estimates show that around 2.3 million Filipinos have CKD.3 The National Kidney and…
-
Media Release /The Philippine Food and Drug Administration (FDA) has approved brolucizumab for the treatment of visual impairment due to diabetic macular edema (DME), a common microvascular complication in…
-
Media Release /The Alliance and Partnerships for Patient Innovation and Solutions (APPIS) platform will hold its third annual virtual Summit on March 20-21, 2023. Organized by Novartis and co-created by the…
-
Media Release /Novartis and the Novartis Foundation have been working with the Department of Health and other partners to eliminate leprosy for over 30 years. The Novartis Foundation focuses on influencing…
-
Media Release /Novartis continuously finds ways to help improve the quality of care for Filipino patients living with cancer, which is one of the leading causes of illness and death in the Philippines. In…
